Armata Pharmaceuticals, Inc.
Every calculator, already run for ARMP
Open the full toolkit →You have the numbers on ARMP. Get the argument.
A written report on which of these readings actually decide the outcome for Armata Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
2 analysts covering ARMPAnalyst Price Target Disagreement for Armata Pharmaceuticals, Inc.
Wall Street's bull case implies +371% from the current price; the bear case implies +253%. A 118% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
ARMP — frequently asked
Is ARMP a buy right now?
Wall Street's consensus rating on Armata Pharmaceuticals, Inc. is none across 2 analysts, with a mean price target of $17.50 (+312% vs. the current $4.25). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ARMP's next earnings date?
Armata Pharmaceuticals, Inc. is next scheduled to report earnings around Aug 12, 2026. A full ARMP research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Armata Pharmaceuticals, Inc.?
Analysts covering Armata Pharmaceuticals, Inc. (ARMP) range from a bear-case target of $15.00 to a bull-case high of $20.00, with a mean consensus target of $17.50 across 2 analysts. The spread of $5.00 (118% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Armata Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Armata Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ARMP research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Armata Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.